Eton Pharmaceuticals(US:ETON) Globenewswire·2025-10-23 20:30Core Viewpoint - Eton Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3]. - The company's commercial products include KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Engagement - Management will take live questions during the conference call and will also answer emailed questions from investors [2]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days after the event [2].